Clinical Trials Browser

Cholangiocarcinoma × Leucovorin × Clear all

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Phase 2 Not yet recruiting

30 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04421820 2026-01-27

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Phase 1/2 Recruiting

220 enrolled

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07265674 2026-01-23

Beacon-BTC

Phase 3 Recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

36 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT07328919 2026-01-09

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

Phase 3 Not yet recruiting

138 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT03044587 2025-10-01

NIFE

Phase 2 Completed

93 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

74 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

138 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07025174 2025-06-17

SAIB

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05712356 2025-06-06

BOLSTER

Phase 2 Active not recruiting

67 enrolled

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06438822 2025-05-07

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

Phase 2 Recruiting

51 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT06648525 2024-10-18

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

Phase 2 Not yet recruiting

68 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05009953 2024-07-11

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Phase 2 Terminated

17 enrolled

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT02333188 2023-05-31

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

Phase 1 Completed

50 enrolled

Gastrointestinal

Gallbladder Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT05489692 2022-08-10

HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma

Completed

43 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT03603834 2021-09-01

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Phase 2 Unknown

25 enrolled

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT04961970 2021-07-14

HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

Phase 3 Unknown

188 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT01926236 2020-01-28

ABC06

Phase 3 Completed

162 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03771846 2019-12-05

HAIC Versus Systemic Chemotherapy for Unresectable ICC

Phase 3 Unknown

188 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT02042443 2017-09-12

S1310

Phase 2 Completed

53 enrolled 13 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma, Klatskin Tumor

NCT01572324 2017-01-04

Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas

Phase 2 Completed

37 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Clinical Trials

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Beacon-BTC

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

NIFE

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

SAIB

BOLSTER

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC

ABC06

HAIC Versus Systemic Chemotherapy for Unresectable ICC

S1310

Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas